$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could Be Next
The Covid Era Tech Promises To Reinvent Cancer Treatment
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Teva Launches First U.S. Generic Against Novartis Antidiarrheal Sandostatin LAR
Pfizer Cuts Haleon Stake in $3.3B Share Sale